In a neonatal unit, where the smallest patients are the most fragile, a stool sample is one of the few things that can be gathered without adding to a child's burden. A French research team has asked how much meaning such a sample might carry about necrotizing enterocolitis, a serious bowel condition that strikes the very premature. Their findings, drawn from 130 infants across several centers, suggest that certain proteins in the stool can tell diagnosed cases apart from those without the disease. Whether this quiet signal can one day help clinicians act sooner remains a question for larger a
Stool Biomarkers Show Promise in Distinguishing Necrotizing Enterocolitis in Preterm Infants
Forty-two preterm infants were diagnosed with confirmed necrotizing enterocolitis, a serious intestinal condition, and their stool samples were analyzed in the study.
A sample that costs the baby nothing
Mark
Why does a stool test matter for NEC specifically?
Mimi
Because the babies are so fragile. A sample costs them nothing, and the 42 infants with confirmed NEC in this study had a serious intestinal illness. Anything that sharpens the assessment without invasive steps is worth testing.
Mark
Which marker came out on top?
Mimi
Secretory IgA, with an AUC of 0.82. Calprotectin was 0.74 and α1-antitrypsin 0.73.
Luke
Worth saying what that number means. It describes how well the marker separated known NEC from known non-NEC. It isn't a measure of how well it would predict NEC in a baby whose diagnosis is still open.
Mark
So the timing matters?
Mimi
Yes. NEC samples were taken at diagnosis, and control samples at comparable ages.
Luke
Which means this shows discrimination, not early warning. The source doesn't claim the tests catch NEC sooner.
Mark
And the combined models?
Mimi
The four-marker model reached 0.83 and the six-marker model 0.86, a modest gain.
Luke
The six-marker figure came from a complete-case model, only infants with all six measurements. The source doesn't say how many that was, so I'd hold that 0.86 loosely. Validation in larger prospective cohorts is still ahead.
Il Polso
- Necrotizing enterocolitis remains one of the most feared threats in neonatal intensive care, where a fragile bowel can turn dangerous within hours.
- Researchers tested six stool markers across 130 preterm infants, 42 of them diagnosed with the condition, to see whether a simple sample could separate sick from healthy.
- Secretory IgA emerged as the strongest single marker, with an AUC of 0.82, pointing toward a noninvasive tool clinicians have long lacked.
- Combining markers into multimarker models improved accuracy only modestly, reaching 0.86, so no panel yet offers a decisive advantage.
- The study compared infants already diagnosed, so whether these tests can detect the disease earlier awaits validation in larger prospective cohorts.
In a neonatal unit, where the smallest patients are the most fragile, a stool sample is one of the few things that can be gathered without adding to a child's burden. A French research team has asked how much meaning such a sample might carry about necrotizing enterocolitis, a serious bowel condition that strikes the very premature. Their findings, drawn from 130 infants across several centers, suggest that certain proteins in the stool can tell diagnosed cases apart from those without the disease. Whether this quiet signal can one day help clinicians act sooner remains a question for larger and more forward-looking studies.
A stool sample from a premature baby is easy to collect and asks almost nothing of the child. A new French study, published in Pediatric Research in October 2026, asks how much such a sample can reveal about necrotizing enterocolitis, a serious intestinal condition that is among the most feared complications in neonatal units.
Earlier research tended to examine one marker at a time, often at a single hospital. This team, led by Diwan and colleagues, drew on a larger French cohort of infants born before 32 weeks and measured six stool markers across several centers. They compared 42 infants diagnosed with NEC against 88 without it, with stool collected at comparable points in early life. The two groups were closely matched on gestational age, with a median of 28 weeks in each.
Secretory IgA performed best on its own, distinguishing the two groups with an area under the curve of 0.82, where 0.5 would be no better than chance. Combining markers helped only modestly, lifting accuracy to 0.86 in a six-marker model.
The researchers describe these markers as promising noninvasive tools. Yet the study looked at infants who already had the diagnosis, so it cannot yet show whether such tests would catch the disease sooner. That question, tested in larger prospective cohorts, is the next step toward whether a simple stool sample might one day help clinicians act earlier.
A stool sample from a premature baby is easy to collect and costs the child nothing. A new French study asks how much that sample can reveal about one of the most feared complications in a neonatal unit, necrotizing enterocolitis, or NEC, a serious intestinal condition of preterm infants.
The work was published online ahead of print in Pediatric Research on October 23, 2026. The authors are Diwan, Delannoy, Ferraris, Rozé, Kapel, Butel and colleagues. It is an ancillary analysis, meaning it draws on a larger French cohort of infants born before 32 weeks of gestation. The question was narrower than the cohort itself: could a panel of stool biomarkers tell infants with NEC from infants without it?
The researchers say earlier work leaned on one marker at a time, usually at a single center. This study measured six markers across multiple centers: fecal calprotectin, human β-defensin-2, α1-antitrypsin, secretory immunoglobulin A (sIgA), cingulin, and eosinophil-derived neurotoxin.
The design was straightforward. For infants with NEC, defined as Bell stage II or higher, stool was collected at the time of diagnosis. For infants without NEC, stool was collected at comparable postnatal ages, so that the two groups were measured at similar points in their early lives.
In all, 130 preterm infants were included. Forty-two had NEC and 88 did not. The groups were well matched on one important variable: the median gestational age was 28 weeks in both, with a p value above 0.9, meaning no meaningful difference.
Secretory IgA performed best on its own, with an area under the curve of 0.82. An AUC of 1.0 would be perfect discrimination, and 0.5 would be no better than a coin flip. Fecal calprotectin followed at 0.74, and α1-antitrypsin at 0.73. Combining markers helped, though not dramatically. A four-marker model using α1-antitrypsin, eosinophil-derived neurotoxin, β-defensin-2 and sIgA reached 0.83. A six-marker model, run only on infants with complete data for all six, reached 0.86.
The authors conclude that stool biomarkers can separate confirmed NEC from non-NEC in preterm infants, that sIgA is the strongest single marker, and that multimarker models do modestly better. They describe the markers as potential noninvasive tools for assessing NEC. The review rates the evidence level 2 (good).
The study compares infants already diagnosed with NEC against those without it. It does not show whether these tests would catch the disease earlier than current methods. Whether the markers hold up in larger prospective cohorts, and whether they can support earlier assessment in neonatal units, is the next test.
Citazioni salienti
Stool biomarkers distinguished infants with confirmed NEC from preterm infants without NEC, with sIgA showing the best individual discrimination, and multimarker models performing modestly better.— Study findings summarized from Diwan et al., Pediatric Research
Vuoi la storia completa?
Leggi l'originale su 2 Minute Medicine ↗
Society & Civil Rights